This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miralem, T.
Right arrow Articles by Avraham, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miralem, T.
Right arrow Articles by Avraham, H. K.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, January 2003, p. 579-593, Vol. 23, No. 2
0270-7306/03/$08.00+0     DOI: 10.1128/MCB.23.2.579-593.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Extracellular Matrix Enhances Heregulin-Dependent BRCA1 Phosphorylation and Suppresses BRCA1 Expression through Its C Terminus

Tiho Miralem and Hava Karsenty Avraham*

Division of Experimental Medicine, Beth Israel-Deaconess Medical Center, Harvard Institutes of Medicine, Boston, Massachusetts 02115

Received 7 May 2002/ Returned for modification 5 July 2002/ Accepted 25 October 2002

Germ line mutations in the breast cancer susceptibility gene BRCA1 account for the increased risk of early onset of familial breast cancer, whereas overexpression of the ErbB family of receptor tyrosine kinases has been linked to the development of nonfamilial or sporadic breast cancer. To analyze whether there is a link between these two regulatory molecules, we studied the effects of ErbB-2 activation by heregulin (HRG) on BRCA1 function. It was previously demonstrated that HRG induced the phosphorylation of BRCA1, which was mediated by the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Since altered interaction between cells and the surrounding extracellular matrix (ECM) is a common feature in a variety of tumors and since ECM modulates intracellular signaling, we hypothesized that ECM may affect the expression and HRG-dependent phosphorylation of BRCA1. Following stimulation by HRG, a strong increase in [3H]thymidine incorporation was observed in human T47D breast cancer cells seeded on plastic (PL). When T47D cells were seeded on laminin (LAM) or Matrigel, HRG induced a significantly higher proliferation than it did in cells seeded on PL. T47D cells seeded on poly-L-lysine had an abrogated mitogenic response, indicating the involvement of integrins in this process. HRG treatment induced a transient phosphorylation of BRCA1 that was enhanced in T47D cells grown on LAM. LAM-enhanced BRCA1 phosphorylation was mediated through {alpha}6 integrin upon HRG stimulation. Accordingly, T47D cells grown on LAM had the greatest increase in ErbB-2 activation, PI3K activity, and phosphorylation of Akt. A similar pattern of BRCA1 mRNA expression was observed when T47D cells were seeded on PL, LAM, or COL4. There was a significant decrease in the steady state of the BRCA1 mRNA level on both the LAM and COL4 matrices compared to that for cells seeded on PL. In addition, HRG stimulation caused a significant decrease in BRCA1 mRNA expression that was dependent on protein synthesis. Pretreatment with both the calpain inhibitor ALLN (N-acetyl-Leu-Leu-norleucinal) and the proteosome inhibitor lactacystin inhibited the HRG-induced down-regulation of BRCA1 mRNA expression. Likewise, there was a strong decrease in the protein level of BRCA1 in T47D cells 4 h after treatment with HRG compared to its level in control nontreated T47D cells. Pretreatment with the proteosome inhibitors ALLN, lactacystin, and PSI [N-benzyloxycarbonyl-Ile-Glu-(O-t-butyl)-Ala-leucinal] inhibited also the HRG-induced down-regulation of BRCA1 protein in breast cancer cells. Interestingly, BRCA1 mRNA expression in HCC-1937 breast cancer cells, which express C-terminally truncated BRCA1, was not affected by either LAM or CL4. No phosphorylation of BRCA1 from HCC-1937 cells was observed in response to HRG. While Cdk4 phosphorylated wild-type BRCA1 in response to HRG in T47D cells, Cdk4 failed to phosphorylate the truncated form of BRCA1 in HCC-1937 cells. Furthermore, overexpression of wild-type BRCA1 in HCC-1937 cells resulted in the phosphorylation of BRCA1 and decreased BRCA1 expression upon HRG stimulation while overexpression of truncated BRCA1 in T47D cells resulted in a lack of BRCA1 phosphorylation and restoration of BRCA1 expression. These findings suggest that ECM enhances HRG-dependent BRCA1 phosphorylation and that ECM and HRG down-regulate BRCA1 expression in breast cancer cells. Furthermore, ECM suppresses BRCA1 expression through the C terminus of BRCA1.

* Corresponding author. Mailing address: Division of Experimental Medicine, Beth Israel-Deaconess Medical Center, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA 02115. Phone: (617) 667-0073. Fax: (617) 975-5240. E-mail: havraham{at}caregroup.harvard.edu.

Molecular and Cellular Biology, January 2003, p. 579-593, Vol. 23, No. 2
0022-538X/03/$08.00+0     DOI: 10.1128/MCB.23.2.579-593.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Xiang, T., Ohashi, A., Huang, Y., Pandita, T. K., Ludwig, T., Powell, S. N., Yang, Q. (2008). Negative Regulation of AKT Activation by BRCA1. Cancer Res. 68: 10040-10044 [Abstract] [Full Text]  
  • Bromberg, K. D., Ma'ayan, A., Neves, S. R., Iyengar, R. (2008). Design Logic of a Cannabinoid Receptor Signaling Network That Triggers Neurite Outgrowth. Science 320: 903-909 [Abstract] [Full Text]  
  • Ma, Y., Hu, C., Riegel, A. T., Fan, S., Rosen, E. M. (2007). Growth Factor Signaling Pathways Modulate BRCA1 Repression of Estrogen Receptor-{alpha} Activity. Mol. Endocrinol. 21: 1905-1923 [Abstract] [Full Text]  
  • Maines, M. D., Miralem, T., Lerner-Marmarosh, N., Shen, J., Gibbs, P. E. M. (2007). Human Biliverdin Reductase, a Previously Unknown Activator of Protein Kinase C betaII. J. Biol. Chem. 282: 8110-8122 [Abstract] [Full Text]  
  • Moro, L., Arbini, A. A., Marra, E., Greco, M. (2005). Down-regulation of BRCA2 Expression by Collagen Type I Promotes Prostate Cancer Cell Proliferation. J. Biol. Chem. 280: 22482-22491 [Abstract] [Full Text]  
  • Miralem, T., Hu, Z., Torno, M. D., Lelli, K. M., Maines, M. D. (2005). Small Interference RNA-mediated Gene Silencing of Human Biliverdin Reductase, but Not That of Heme Oxygenase-1, Attenuates Arsenite-mediated Induction of the Oxygenase and Increases Apoptosis in 293A Kidney Cells. J. Biol. Chem. 280: 17084-17092 [Abstract] [Full Text]  
  • Zhang, J., Zhu, J., Bu, X., Cushion, M., Kinane, T. B., Avraham, H., Koziel, H. (2005). Cdc42 and RhoB Activation Are Required for Mannose Receptor-mediated Phagocytosis by Human Alveolar Macrophages. Mol. Biol. Cell 16: 824-834 [Abstract] [Full Text]  
  • Kravets, A., Hu, Z., Miralem, T., Torno, M. D., Maines, M. D. (2004). Biliverdin Reductase, a Novel Regulator for Induction of Activating Transcription Factor-2 and Heme Oxygenase-1. J. Biol. Chem. 279: 19916-19923 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»